RxDoctor Payments Data

Mario Lopez Esqueda

Family · Brawley, CANPI 1154891430

Payments from drug & device makers

$2,684in general payments, 2019–2025

Across 137 payments — averaging $19.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • MDD US Operations, LLC$409
  • AbbVie$385
  • Neurocrine Biosciences, Inc.$306
  • Nevro Corp.$300
  • Biohaven Pharmaceutical Holding Company Ltd.$190
  • Acadia Pharmaceuticals Inc$184
  • plus $909 from 18 others

What the payments were for

  • Travel & lodging$2499%
  • Food & beverage$2,43691%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,684 in reported general payments places this provider in the 85th percentile of 10,634 family providers in California.

See all family providers in California

Most prescribed under Part D

DrugClaimsCost to plans & patients
NamzaricMemantine Hcl/Donepezil Hcl239$157,983
Nurtec OdtRimegepant Sulfate64$103,462
EliquisApixaban149$89,489
AptiomEslicarbazepine Acetate52$84,176
NuplazidPimavanserin Tartrate13$58,004
UbrelvyUbrogepant48$55,079
Aimovig AutoinjectorErenumab-Aooe56$45,045
EpidiolexCannabidiol (Cbd)11$37,161
RexultiBrexpiprazole24$34,570
XareltoRivaroxaban50$31,371
Memantine Hcl1,643$29,740
Lidocaine265$23,546
QuliptaAtogepant18$20,853
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen821$19,959
Buprenorphine75$18,619

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieNamzaric, Ubrelvy, Qulipta$385$233,914305 claims
PfizerNurtec Odt, Eliquis$52$192,951213 claims
Acadia Pharmaceuticals IncNuplazid$184$58,00413 claims
Otsuka America Pharmaceutical, Inc.Rexulti$75$34,57024 claims
Johnson & JohnsonXarelto$20$31,37150 claims
AstraZenecaBrilinta$18$10,71125 claims
Redhill Biopharma Inc.Movantik$16$8,68522 claims
Amneal Pharmaceuticals LLCRytary$68$6,08015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,634 family providers in California.

Other family in Brawley

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →